Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription 26.02.2024 2 Ann Intern Med 5 BMJ 2 Clin Infect Dis 1 J Immunol 1 J Infect Dis 3 J Virol 2 Lancet 1 MMWR Morb Mortal Wkly Rep 1 N Engl J Med 2 Nat Immunol 3 Pediatr Infect Dis J 5 PLoS One 18 Vaccine 2 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Intern Med

1. CENTOR RM, Tenforde MW, Dawood FS
   Web Exclusive. Annals On Call - Encouraging Influenza Vaccination.
   Ann Intern Med. 2024;177:eA230004.
   PubMed        
   
   
2. WU Q, Tong J, Zhang B, Zhang D, et al
   Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents.
   Ann Intern Med. 2024 Jan 9. doi: 10.7326/M23-1754.
   PubMed         Abstract available
   
   

   
   BMJ

3. NOLAN T
   RSV vaccination roll-outs and electronic nicotine delivery systems.
   BMJ. 2024;384:q427.
   PubMed        
   
   
4. WORSHAM CM, Bray CF, Jena AB
   Optimal timing of influenza vaccination in young children: population based cohort study.
   BMJ. 2024;384:e077076.
   PubMed         Abstract available
   
   
5. 
   Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study.
   BMJ. 2024;384:q434.
   PubMed        
   
   
6. WISE J
   GMC admits error in decision over whether to investigate doctor's claims over covid vaccine.
   BMJ. 2024;384:q433.
   PubMed        
   
   
7. MAHASE E
   Measles: 500 cases are confirmed in England as clusters appear around the country.
   BMJ. 2024;384:q417.
   PubMed        
   
   

   
   Clin Infect Dis

8. FOLLMANN D, Mateja A, Fay MP, Magaret CA, et al
   Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine.
   Clin Infect Dis. 2024 Feb 19:ciae081. doi: 10.1093.
   PubMed         Abstract available
   
   
9. TOEPFER AP, Amarin JZ, Spieker AJ, Stewart LS, et al
   Seasonality, clinical characteristics, and outcomes of respiratory syncytial virus disease by subtype among children less than five years old, New Vaccine Surveillance Network, United States, 2016-2020.
   Clin Infect Dis. 2024 Feb 15:ciae085. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Immunol

10. AL-AHMAD A
    Comment on "Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines".
    J Immunol. 2024;212:753.
    PubMed        
    
    

    
    J Infect Dis

11. SHAW CA, Essink B, Harper C, Mithani R, et al
    Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase I Clinical Trial in Healthy Older Adults.
    J Infect Dis. 2024 Feb 22:jiae081. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

12. ISHIYAMA R, Yoshida K, Oikawa K, Takai-Todaka R, et al
    Production of infectious reporter murine norovirus by VP2 trans-complementation.
    J Virol. 2024;98:e0126123.
    PubMed         Abstract available
    
    
13. DULIN H, Barre RS, Xu D, Neal A, et al
    Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.
    J Virol. 2024 Jan 11:e0157123. doi: 10.1128/jvi.01571.
    PubMed         Abstract available
    
    
14. HE Y, Guo Z, Subiaur S, Benegal A, et al
    Antibody inhibition of influenza A virus assembly and release.
    J Virol. 2024 Jan 5:e0139823. doi: 10.1128/jvi.01398.
    PubMed         Abstract available
    
    

    
    Lancet

15. HUANG S, Zhang X, Su Y, Zhuang C, et al
    Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2024 Feb 19:S0140-6736(23)02234-1. doi: 10.1016/S0140-6736(23)02234.
    PubMed         Abstract available
    
    
16. ABRAVANEL F, Lhomme S
    Hecolin vaccine: long-term efficacy against HEV for a three-dose regimen.
    Lancet. 2024 Feb 19:S0140-6736(23)02455-8. doi: 10.1016/S0140-6736(23)02455.
    PubMed        
    
    

    
    MMWR Morb Mortal Wkly Rep

17. MUSA N, Ghoniem A, Hsu CH, Mubarak S, et al
    Progress Toward Measles Elimination - World Health Organization Eastern Mediterranean Region, 2019-2022.
    MMWR Morb Mortal Wkly Rep. 2024;73:139-144.
    PubMed         Abstract available
    
    

    
    N Engl J Med

18. 
    Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2024;390:772.
    PubMed        
    
    

    
    Nat Immunol

19. 
    A nasal vaccine elicits protective CD8(+) T cell immunity against antigen shifted SARS-CoV-2 virus.
    Nat Immunol. 2024 Feb 20. doi: 10.1038/s41590-024-01744.
    PubMed        
    
    
20. 
    A mechanism for BCG vaccine cross-protection against pulmonary viral infections.
    Nat Immunol. 2024 Feb 21. doi: 10.1038/s41590-024-01775.
    PubMed        
    
    

    
    Pediatr Infect Dis J

21. KUSHNER LE, Kamens J, Bertaina A, Shyr D, et al
    Vaccine Associated Measles Complicated by Suspected Measles Inclusion Body Encephalitis in a Pediatric Leukemia Patient and Stem Cell Transplant Recipient: A Focus on Clinical Evolution and Management.
    Pediatr Infect Dis J. 2024 Feb 21. doi: 10.1097/INF.0000000000004299.
    PubMed         Abstract available
    
    
22. LEE KS, Kim YK, Choi YY, Choe YJ, et al
    Risk Factors for Severe and Critical Coronavirus Disease 2019 in Children.
    Pediatr Infect Dis J. 2024;43:234-241.
    PubMed         Abstract available
    
    
23. FUJI N, Pham M, Kaur R, E Pichichero M, et al
    Serotype 3 Antibody Response and Antibody Functionality Compared to Serotype 19A Following 13-Valent Pneumococcal Conjugate Immunization in Children.
    Pediatr Infect Dis J. 2024;43:294-300.
    PubMed         Abstract available
    
    

    
    PLoS One

24. ADINKRAH EK, Bazargan S, Cobb S, Kibe LW, et al
    Mobilizing faith-based COVID-19 health ambassadors to address COVID-19 health disparities among African American older adults in under-resourced communities: A hybrid, community-based participatory intervention.
    PLoS One. 2024;19:e0285963.
    PubMed         Abstract available
    
    
25. BEN-UMEH KC, Kim J
    Income disparities in COVID-19 vaccine and booster uptake in the United States: An analysis of cross-sectional data from the Medical Expenditure Panel Survey.
    PLoS One. 2024;19:e0298825.
    PubMed         Abstract available
    
    
26. JEONG HS, Chun BC
    COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barre Syndrome, and mortality in South Korea using a nationwide population-based cohort study.
    PLoS One. 2024;19:e0297902.
    PubMed         Abstract available
    
    
27. GILANO G, Sako S, Molla B, Dekker A, et al
    The effect of mHealth on childhood vaccination in Africa: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0294442.
    PubMed         Abstract available
    
    
28. BALEGHA AN, Abdul-Aziz S, Mornah L
    Healthcare professionals' perception and COVID-19 vaccination attitudes in North-Western Ghana: A multi-center analysis.
    PLoS One. 2024;19:e0298810.
    PubMed         Abstract available
    
    

    
    Vaccine

29. XU S, Sy LS, Hong V, Farrington P, et al
    Mortality risk after COVID-19 vaccination: A self-controlled case series study.
    Vaccine. 2024 Feb 21:S0264-410X(24)00191-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
30. PLIESKATT J, Bang P, Wood GK, Naghizadeh M, et al
    Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP.
    Vaccine. 2024 Feb 21:S0264-410X(24)00202-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
31. BOTTCHER J, Bauer BU, Ambros C, Alex M, et al
    The immune response to a Coxiella burnetii vaccine in sheep varies according to their natural pre-exposure.
    Vaccine. 2024 Feb 21:S0264-410X(24)00207-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
32. YIN Q, Zheng Y, Ying Z, Li J, et al
    Immunogenicity and lot-to-lot consistency of booster shot with Sabin inactivated poliomyelitis vaccine in Chinese children aged 18-24 Months: A phase ? clinical trial.
    Vaccine. 2024 Feb 21:S0264-410X(24)00201-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
33. KABORE L, Pecenka C, Hausdorff WP
    Lassa fever vaccine use cases and demand: Perspectives from select West African experts.
    Vaccine. 2024 Feb 17:S0264-410X(24)00203-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
34. BRUEL S, Rakotomampionona Z, Gignon M, Agrinier N, et al
    The intentions of French health university students to recommend and to receive the HPV vaccine are mainly influenced by vaccine knowledge, confidence in vaccines and personal HPV vaccination.
    Vaccine. 2024 Feb 17:S0264-410X(24)00192-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
35. SHOUKAT A, Bawden CE, Rost G, LeBlanc JJ, et al
    Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2024 Feb 16:S0264-410X(24)00200-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
36. LUGELO A, Hampson K, McElhinney LM, Lankester F, et al
    Evaluation of an iELISA for detection and quantification of rabies antibodies in domestic dog sera.
    Vaccine. 2023 Sep 14:S0264-410X(23)01058-7. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    
37. KUTER BJ, Brien K, Anderson S, Bass SB, et al
    COVID-19 vaccine perspectives and uptake among university students three years into the pandemic.
    Vaccine. 2024 Feb 15:S0264-410X(24)00162-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
38. KIM HK, Park SK, Choe SA, Gwak ES, et al
    Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study.
    Vaccine. 2024 Feb 15:S0264-410X(24)00168-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
39. ROCKSON ADJEI M, Longsignikuu A, Saeed Iddris I, Nang Suuri T, et al
    Trend of measles-rubella vaccination coverage and impact on measles epidemiology in the Savannah Region, Ghana; 2018-2022: A secondary data analysis.
    Vaccine. 2024 Feb 15:S0264-410X(24)00170-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
40. THIAUCOURT F, Exbrayat A, Loire E, Boissiere A, et al
    Deep sequencing and variant frequency analysis for the quality control of a live bacterial vaccine against contagious bovine pleuropneumonia, strain T1.
    Vaccine. 2024 Feb 15:S0264-410X(24)00177-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
41. TOBACK S, Marchese AM, Warren B, Ayman S, et al
    Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.
    Vaccine. 2024 Feb 15:S0264-410X(24)00196-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
42. MZIOU E, Hchaichi A, Letaief H, Dhaouadi S, et al
    Vaccine effectiveness against COVID-19: A test negative case-control study in Tunisia, August 2021.
    Vaccine. 2024 Feb 15:S0264-410X(24)00174-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
43. FABER BW, Yeoh LM, Kurtovic L, Mol WEM, et al
    A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies.
    Vaccine. 2024 Feb 16:S0264-410X(24)00175-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
44. JIN F, Qiu Y, Wu Z, Wang YH, et al
    Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
    Vaccine. 2024 Feb 15:S0264-410X(24)00124-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
45. POLAND GA, Raina MacIntyre C
    Celebrating vaccines: The 2023 Nobel prize in medicine or physiology.
    Vaccine. 2024 Feb 15:S0264-410X(23)01258-6. doi: 10.1016/j.vaccine.2023.
    PubMed        
    
    
46. PIKE J, Lueken J, Zajac J, Tippins A, et al
    2022 Polio outbreak, Rockland County, NY: Cost evaluation of strategies to prevent future outbreaks of vaccine-preventable diseases.
    Vaccine. 2024 Feb 16:S0264-410X(24)00171-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    

    
    Virology

47. MA B, Tao M, Li Z, Zheng Q, et al
    Mucosal vaccines for viral diseases: Status and prospects.
    Virology. 2024;593:110026.
    PubMed         Abstract available
    
    
48. ZHANG F, Chai Z, Wang X, Zhang Z, et al
    Monkeypox: Can we count on the current smallpox immunization?
    Virology. 2024;592:109994.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.